Quantcast

Personalized Medicine Partnering Terms and Agreements

May 7, 2014

LONDON, May 7, 2014 /PRNewswire/ — Reportbuyer.com has added a new market research report:

Personalized Medicine Partnering Terms and Agreements

http://www.reportbuyer.com/pharma_healthcare/treatments/personalized_medicine_partnering_terms_agreements.html

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a review of the leading companion diagnostic deals since 2009. Deals are listed by headline value, sig ned by bigpharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a review of the leading pharmacogenomics deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive and detailed review of personalized medicine partnering deals signed and announced since January 2009. The chapter is organized by specific personalized medicine, biomarkers, companion diagnostics and pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

Personalized Medicine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to personalized medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

o Trends in personalized medicine dealmaking in the biopharma industry since 2009
o Analysis of personalized medicine deal structure
o Access to headline, upfront, milestone and royalty data and contract documents
o Case studies of real-life personalized medicine deals
o Access to over 1000 personalized medicine deal announcements
o The leading personalized medicine deals by value since 2009
o Most active personalized medicine dealmakers since 2007
o The leading personalized medicine partnering resources In Personalized Medicine Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1000 personalized medicine deals. Analyzing actual contract agreements allows assessment of the following:

o What are the precise personalized medicine rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture? o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?

Number of pages: The report is comprised of 1,289 pages including appendices.

Personalized Medicine Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of personalized medicine deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of personalized medicine agreements with numerous real life case studies
Comprehensive access to over 1000 actual personalized medicine deals entered into by the world’s biopharma companies
Detailed access to actual personalized medicine contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a personalized medicine agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
TABLE OF CONTENTS

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in personalized medicine dealmaking

2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Big pharma most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type
2.7 Average deal terms for personalized medicine
2.7.1 Personalized medicine headline values
2.7.2 Personalized medicine upfront payments
2.7.3 Personalized medicine milestone payments
2.7.4 Personalized medicine royalty rates
Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving big pharma

Chapter 4 – Leading companion diagnostic deals

4.1. Introduction
4.2. Top companion diagnostic deals by value
4.3. Top companion diagnostic deals involving big pharma

Chapter 5 – Leading pharmacogenomics deals

5.1. Introduction
5.2. Top pharmacogenomics deals by value

Chapter 6 – Big pharma personalized medicine deals

6.1. Introduction
6.2. How to use big pharma personalized medicine partnering deals
6.3. Big pharma personalized medicine partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB

Chapter 7 – Biomarker contracts dealmaking directory

7.1. Introduction
7.2. By Company A-Z
Abbott Laboratories
Adamis Pharmaceuticals
ADMA Biologics
Altair Nanotechnologies
Amarantus BioSciences
ARCA Biopharma
Arno Therapeutics
Arrayit
Arrayit Diagnostics
Avalon Pharmaceuticals
BG Medicine
Biogen Idec
Biotage
Caliper Life Sciences
Celera
Clinical Data
Columbia University
DeCODE Genetics
DiagnoCure
Enterome Bioscience
Galmed Pharmaceuticals
Gen-Probe
Genzyme
Genzyme Genetics
GlaxoSmithKline
Guided Therapeutics
Health Discovery
Intrexon
Inverness Medical Innovations
Invivis Pharmaceuticals
KineMed
Konica Minolta
Laboratory Corporation of America
Merck and Co
Novartis
Perugia University
Power3 Medical Products
Psynova Neurotech
Quest Diagnostics
Regulus Therapeutics
Response Genetics
Roche
Rules-Based Medicine
Sanofi
Skyline Diagnostics
The Regents of the University of California
Transgenomic
TrovaGene
University of Cambridge
University of Cincinnati
US Army
Wayne State University
Zora Biosciences
7.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
7.4. By therapy type
Cardiovascular
Central Nervous System
Genetic disorders
Metabolic
Musculoskeletal
Oncology
Respiratory

Chapter 8 – Companion diagnostic contracts dealmaking directory

8.1. Introduction
8.2. By Company A-Z
Achaogen
AmpliPhi Biosciences
ARK Diagnostics
Arno Therapeutics
BG Medicine
Biogen Idec
Celladon
Galmed Pharmaceuticals
Health Diagnostic Laboratory
Invivis Pharmaceuticals
Photocure ASA
Psynova Neurotech
Regulus Therapeutics
Roche
Rules-Based Medicine
Salix Pharmaceuticals
Verastem
Virovek
Whitehead Institute
Zora Biosciences
8.3. By deal type
Co-development
Collaborative R&D
Contract service
Development
Distribution
Licensing
Marketing
Option
Sub-license
8.4. By therapy area
Cardiovascular
Central Nervous System
Infectives
Metabolic
Oncology
Psychiatry

Chapter 9 – Pharmacogenomics contracts dealmaking directory

9.1. Introduction
9.2. By Company A-Z
America Stem Cell
Cephalon
Champions Oncology
Clinical Data
DARA BioSciences
GlaxoSmithKline
Response Genetics
Transgenomic
9.3. By deal type
Asset purchase
Collaborative R&D
Licensing
Material transfer
9.4. By therapy type
Hematology
Hospital care
Oncology

Chapter 10 – Personalized Medicine dealmaking directory by specific technology type

Personalized medicine
Pharmacogenomics
Biomarkers
Companion Diagnostics

Chapter 11 – Personalized medicine partnering resource center

11.1. Online personalized medicine partnering
11.2. Personalized medicine partnering events
11.3. Further reading on personalized medicine dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Personalized medicine partnering since 2009
Figure 2: Biomarker partnering since 2009
Figure 3: Companion diagnostic partnering since 2009
Figure 4: Pharmacogenomics partnering since 2009
Figure 5: Bigpharma – top 50 – personalized medicine deals 2009 to 2014
Figure 6: Big pharma personalized medicine deal frequency – 2009 to 2014
Figure 7: Big pharma – top 50 – biomarker, companion diagnostic and pharmacogenomics deals 2009 to 2014
Figure 8: Big pharma biomarker deal frequency – 2009 to 2014
Figure 9: Big pharma companion diagnostic deal frequency – 2009 to 2014
Figure 10: Big pharma pharmacogenomics deal frequency – 2009 to 2014
Figure 11: Most active big pharma in personalized medicine 2009-2014
Figure 12: Most active bigpharma in biomarkers 2009-2014
Figure 13: Most active bigpharma in companion diagnostic 2009-2014
Figure 14: Most active bigpharma pharmacogenomics dealmaking activity 2009-2014
Figure 15: Personalized medicine partnering by deal type since 2009
Figure 16: Biomarker partnering by deal type since 2009
Figure 17: Companion diagnositc partnering by deal type since 2009
Figure 18: Pharmacogenomics partnering by deal type since 2009
Figure 19: Personalized medicine partnering by disease type since 2009
Figure 20: Personalized medicine partnering by oncology target since 2009
Figure 21: Biomarker partnering by disease type since 2009
Figure 22: Biomarker partnering by oncology target since 2009
Figure 23: Companion diagnostic partnering by disease type since 2009
Figure 24: Companion diagnostic partnering by oncology target since 2009
Figure 25: Pharmacogenomics partnering by disease type since 2009
Figure 26: Pharmacogenomics partnering by oncology target since 2009
Figure 27: Personalized medicine deals with a headline value
Figure 28: Personalized medicine deals headline value distribution, US$m – 2009-2014: discovery
Figure 29: Personalized medicine deals headline value distribution, US$m – 2009-2014: preclinical
Figure 30: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase I
Figure 31: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase II
Figure 32: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase III
Figure 33: Personalized medicine deals headline value distribution, US$m – 2009-2014: regulatory
Figure 34: Personalized medicine deals headline value distribution, US$m – 2009-2014: marketed stage
Figure 35: Summary median headline value by stage of development, 2009-2014
Figure 36: Personalized medicine deals with an upfront value
Figure 37: Personalized medicine deals upfront value distribution, US$m – 2009-2014: discovery
Figure 38: Personalized medicine deals upfront value distribution, US$m – 2009-2014: preclinical
Figure 39: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase I
Figure 40: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase II
Figure 41: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase III
Figure 42: Personalized medicine deals upfront value distribution, US$m – 2009-2014: regulatory
Figure 43: Personalized medicine deals upfront value distribution, US$m – 2009-2014: marketed
Figure 44: Summary median upfront value by stage of development, 2009-2014
Figure 45: Personalized medicine deals with a milestone value
Figure 46: Personalized medicine deals milestone value distribution, US$m – 2009-2014: discovery
Figure 47: Personalized medicine deals milestone value distribution, US$m – 2009-2014: preclinical
Figure 48: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase I
Figure 49: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase II
Figure 50: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase III
Figure 51: Personalized medicine deals milestone value distribution, US$m – 2009-2014: regulatory
Figure 52: Personalized medicine deals milestone value distribution, US$m – 2009-2014: marketed
Figure 53: Personalized medicine deals with a royalty rate value
Figure 54: Personalized medicine deals royalty rate value distribution, % – 2009-2014: discovery
Figure 55: Personalized medicine deals royalty rate value distribution, % – 2009-2014: preclinical
Figure 56: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase I
Figure 57: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase II
Figure 58: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase III
Figure 59: Personalized medicine deals royalty rate value distribution % – 2009-2014: regulatory
Figure 60: Personalized medicine deals royalty rate value distribution, % – 2009-2014: marketed stage
Figure 61: Summary median royalty rate value % by stage of development, 2009-2014
Figure 62: Top biomarker deals by value since 2009
Figure 63: Top biomarker deals signed by big pharma value since 2009
Figure 64: Top companion diagnostic deals by value since 2009
Figure 65: Top companion diagnostic deals signed by big pharma value since 2009
Figure 66: Top pharmacogenomics deals by value since 2009
Figure 67: Online partnering resources
Figure 68: Forthcoming partnering events


Read the full report:
Personalized Medicine Partnering Terms and Agreements

http://www.reportbuyer.com/pharma_healthcare/treatments/personalized_medicine_partnering_terms_agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


Source: PR Newswire



comments powered by Disqus